FREE Equity Delivery and MF
Flat ₹20/trade Intra-day/F&O
|
Comparision between Infollion Research Services IPO and Remus Pharmaceuticals IPO.
Infollion Research Services IPO is a SME Book Built Issue IPO proposed to list at NSE SME while Remus Pharmaceuticals IPO is a SME Book Built Issue proposed to list at NSE SME.
Infollion Research Services IPO | Remus Pharmaceuticals IPO | |
---|---|---|
Logo | ||
Issue Category | SME | SME |
Issue Type | IPO | IPO |
Process Type | Book Built Issue | Book Built Issue |
Listing At | NSE SME | NSE SME |
Lead Managers | Holani Consultants Private Limited | Beeline Capital Advisors Pvt Ltd |
Registrar | Link Intime India Private Ltd | Link Intime India Private Ltd |
Market Maker | Holani Consultants Private Limited | Sunflower Broking Private Limited |
DRHP | DRHP | DRHP |
RHP | RHP | RHP |
Anchor Investor | Anchor Investor | Anchor Investor |
IPO Allotment URL | IPO Allotment URL | IPO Allotment URL |
The total issue size of Infollion Research Services IPO is up to ₹21.45 Cr whereas the issue size of the Remus Pharmaceuticals IPO is up to ₹47.69 Cr. The final issue price of Infollion Research Services IPO is ₹82.00 per share and of Remus Pharmaceuticals IPO is ₹1,229.00 per share.
Infollion Research Services IPO | Remus Pharmaceuticals IPO | |
---|---|---|
Face Value | ₹10 per share | ₹10 per share |
Issue Price (Lower) | ₹80.00 per share | ₹1,150.00 per share |
Issue Price (Upper) | ₹82.00 per share | ₹1,229.00 per share |
Issue Price (Final) | ₹82.00 per share | ₹1,229.00 per share |
Discount (Retail) | ||
Discount (Employee) | ||
Market Lot Size | 1600 shares | 100 shares |
Fresh Issue Size | 22,24,000 shares | 3,88,000 shares |
Fresh Issue Size (Amount) | up to ₹18.24 Cr | up to ₹47.69 Cr |
OFS Issue Size | 3,92,000 shares | |
OFS Issue Size (Amount) | up to ₹3.21 Cr | |
Issue Size Total | 26,16,000 shares | 3,88,000 shares |
Issue Size Total (Amount) | up to ₹21.45 Cr | up to ₹47.69 Cr |
Infollion Research Services IPO opens on May 29, 2023, while Remus Pharmaceuticals IPO opens on May 17, 2023. The closing date of Infollion Research Services IPO and Remus Pharmaceuticals IPO is May 31, 2023, and May 19, 2023, respectively.
Infollion Research Services IPO | Remus Pharmaceuticals IPO | |
---|---|---|
Anchor Bid Date | May 26, 2023 | May 16, 2023 |
Issue Open | May 29, 2023 | May 17, 2023 |
Issue Close | May 31, 2023 | May 19, 2023 |
Basis Of Allotment (Tentative) | Jun 05, 2023 | May 24, 2023 |
Initiation of Refunds (Tentative) | Jun 06, 2023 | May 25, 2023 |
Credit of Share (Tentative) | Jun 07, 2023 | May 26, 2023 |
Listing date (Tentative) | Jun 08, 2023 | May 29, 2023 |
Anchor Lockin End date 1 | Jul 05, 2023 | Jun 23, 2023 |
Anchor Lockin End date 2 | Sep 03, 2023 | Aug 22, 2023 |
Infollion Research Services IPO P/E ratio is 14.24, as compared to Remus Pharmaceuticals IPO P/E ratio of 21.09.
Infollion Research Services IPO | Remus Pharmaceuticals IPO | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Financial |
|
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Promoter Shareholding (Pre-Issue) | 67.09% | 92.82% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Promoter Shareholding (Post-Issue) | 68.37% | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
P/E Ratio | 14.24 | 21.09 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Market Cap | ₹79.47 Cr. | ₹181.03 Cr. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
ROE | 42.20%% | 71.44%% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
ROCE | 69.99%% | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt/Equity | 0.03 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
EPS | ₹33.86 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
RoNW | 52.64%% |
In the Infollion Research Services IPO retail investors (RII) are offered 8,70,400 shares while in Remus Pharmaceuticals IPO retail investors are offered 8,70,400 shares. Qualified institutional buyers (QIB) are offered 4,83,200 shares in Infollion Research Services IPO and 1,38,750 shares in Remus Pharmaceuticals IPO.
Infollion Research Services IPO | Remus Pharmaceuticals IPO | |
---|---|---|
Anchor Investor Reserveration | 7,24,800 shares | 1,10,500 shares |
Market Maker Reserveration | 1,32,800 shares | 19,500 shares |
QIB | 4,83,200 shares | 1,38,750 shares |
NII | 4,04,800 shares | 41,625 shares |
RII | 8,70,400 shares | 97,125 shares |
Employee | 0 shares | 0 shares |
Others | ||
Total | 17,58,400 shares | 2,77,500 shares |
Infollion Research Services IPO subscribed 279.24x in total, whereas Remus Pharmaceuticals IPO subscribed 57.21x.
Infollion Research Services IPO | Remus Pharmaceuticals IPO | |
---|---|---|
QIB (times) | 70.72x | 10.75x |
NII (times) | 560.71x | 229.31x |
Big NII (times) | ||
Small NII (times) | ||
RII (times) | 264.10x | 49.81x |
Employee (times) | ||
Other (times) | ||
Total (times) | 279.24x | 57.21x |
Add a public comment...
FREE Intraday Trading (Eq, F&O)
Flat ₹20 Per Trade in F&O
|